liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infetion
Swedish Institute for Infectious Disease Control (SMI), Solna, Sweden.
Swedish Institute for Infectious Disease Control (SMI), Solna, Sweden.
Swedish Institute for Infectious Disease Control (SMI), Solna, Sweden.
Norwegian institute of Public Health, Oslo, Norway.
Show others and affiliations
2009 (English)In: APMIS: Acta pathologica, microbiologica et immunologica Scandinavica. Supplementum, ISSN 0903-465X, E-ISSN 1600-5503, Vol. 117, no 9, 660-671 p.Article in journal (Refereed) Published
Abstract [en]

The anti-Fim response and long-term persistence after vaccination and infection may be of importance in understanding population immunity. Longitudinal serum samples (n = 1330) from 542 non-infected children related to a Swedish vaccine trial showed that the post vaccination (DTPa5) antibody decay curve for pertussis ELISA IgG anti-fimbriae2/3 (anti-Fim2/3) was bi-phasic. A slower one followed an initial rapid decay approximately 5-6 months after the third dose at 12 months of age. After 71 months, however, 60% still had concentrations above > or =5 EU/ml, a level that had been shown to correlate with decreased risk of disease. Booster responses after re-vaccination with DTPa5 at 4, 5 and 6 years of age were strong and appeared within 1 week after vaccination, indicating immune memory. Ninety-six young children with verified pertussis infection, for whom we had serum samples both before, during and after the infection, showed a high response if they had been primed with fimbriae (either DTPa5 or DTPwc). In contrast, 76% of infected children not primed with fimbriae (a DTPa2 or DT group) only had concentrations below the minimum level of detection in all samples taken during and after the infection. In two Swedish seroepidemiological surveys, one from 1997 just after reintroduction of universal childhood vaccination against pertussis and one from 2007, the proportion of children 2-3 years with anti-Fim2/3 concentrations <5 EU/ml was similar and above 90%. This reflects that the two- or three-component pertussis vaccines (DTPa2 and DTPa3) that were introduced in Sweden in 1996 do not induce anti-Fim2/3 antibodies. In previous studies it was shown in multivariate analyses that levels of IgG anti-Fim2/3 > or =5 EU/ml reduced short-term risk of pertussis in small children. As the antibody response to Fim2/3 after infection is poor in children who have not been primed earlier in life, inclusion of immunogenic Fim2/3 in future pertussis vaccines should be considered.

Place, publisher, year, edition, pages
Wiley-Blackwell, 2009. Vol. 117, no 9, 660-671 p.
Keyword [en]
Pertussis; fimbriae; ELISA IgG anti-Fim2/3; kinetics; vaccination; booster; infection; seroepidemiology; Sweden
National Category
Other Basic Medicine
URN: urn:nbn:se:liu:diva-86453DOI: 10.1111/j.1600-0463.2009.02521.xISI: 000269137300004PubMedID: 19703126OAI: diva2:577637
Available from: 2012-12-15 Created: 2012-12-15 Last updated: 2015-10-23Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Nilsson, Lennart
By organisation
Allergy CentreFaculty of Health SciencesAllergy Center
In the same journal
APMIS: Acta pathologica, microbiologica et immunologica Scandinavica. Supplementum
Other Basic Medicine

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 93 hits
ReferencesLink to record
Permanent link

Direct link